Revumenib for Patients with Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by Prior Treatment in the Phase 2 AUGMENT-101 Study

Poster Presentation | Dec 6, 2025

Author

Arellano ML, et al.

Congress

American Society of Hematology Annual Meeting 2025

Orlando, Florida | Dec 6 – 9, 2025